-
Tytuł:
-
Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
-
Autorzy:
-
Raturi M; Department of Immunohematology and Blood Transfusion, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Swami Ram Nagar, Jolly Grant, 248016 Dehradun, Uttarakhand, India. Electronic address: .
Kusum A; Department of Pathology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Swami Ram Nagar, Jolly Grant, 248016 Dehradun, Uttarakhand, India.
Kala M; Department of Pathology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Swami Ram Nagar, Jolly Grant, 248016 Dehradun, Uttarakhand, India.
Mittal G; Department of Microbiology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Swami Ram Nagar, Jolly Grant, 248016 Dehradun, Uttarakhand, India.
Sharma A; Department of Biochemistry, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Swami Ram Nagar, Jolly Grant, 248016 Dehradun, Uttarakhand, India.
Bansal N; Department of Transfusion Medicine, VCSG Government Institute of Medical Science and Research, Srinagar, Uttarakhand, India.
-
Źródło:
-
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine [Transfus Clin Biol] 2021 Aug; Vol. 28 (3), pp. 300-302. Date of Electronic Publication: 2021 May 07.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Paris : Elsevier Science
Original Publication: Paris : Arnette Blackwell, c1994-
-
MeSH Terms:
-
Geography, Medical*
Pandemics*
Antibodies, Viral/*therapeutic use
COVID-19/*therapy
SARS-CoV-2/*immunology
Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/therapeutic use ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; COVID-19/blood ; COVID-19/epidemiology ; COVID-19/virology ; Communicable Disease Control/methods ; Forecasting ; Humans ; Immunization, Passive ; India/epidemiology ; Mutation ; SARS-CoV-2/genetics ; COVID-19 Serotherapy
-
Contributed Indexing:
-
Keywords: Blood donors; Blood safety; COVID-19 convalescent plasma; Donor registry; Pandemic; Vaccine impact; Viral variants
-
Substance Nomenclature:
-
0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
-
Entry Date(s):
-
Date Created: 20210510 Date Completed: 20210820 Latest Revision: 20221207
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC8103771
-
DOI:
-
10.1016/j.tracli.2021.05.003
-
PMID:
-
33971318
-
The only effective way to provide individuals with herd immunity against the novel coronavirus [SARS-CoV-2] is to administer an effective vaccine that will help check the current pandemic status. In India, the central drugs standard control organization (CDSCO) has granted the emergency-use authorization [EUA] to three vaccines namely, Covishield (live vaccine, Oxford AstraZeneca, United Kingdom being manufactured by the Serum Institute of India), Covaxin (inactivated vaccine, Bharat Biotech, India) and Sputnik V (live vaccine, Gamaleya, Russia). However, there is a rising need for the efficacy of the vaccines to be proven against the "SARS-CoV-2 viral variants." Also, human plasma is polyclonal in nature with an inherent propensity to identify multiple epitopes of either an antigen or pathogen. With this context in mind, the researchers hypothesize that using COVID-19 convalescent plasma [CCP] harvested from the locally recovered individuals [i.e. potential CCP donors] may be particularly beneficial in combating not only the founder SARS-CoV-2 virus but also the geographically determined SARS-CoV-2 variants among the regionally affected COVID-19 patients.
(Copyright © 2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.)
